Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-04-18
- Target Recruit Count
- 200
- Registration Number
- NCT04066764
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Yantai Yuhuangding Hospital, Yantai, Shangdong, China
🇨🇳Shanghai 5th People's Hospital, Shanghai, Shanghai, China
Dabigatran for Mitral Stenosis Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 370
- Registration Number
- NCT04045093
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
DOAC Versus VKA After Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Laval University
- Registration Number
- NCT04002011
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis
- Conditions
- Interventions
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 151
- Registration Number
- NCT03987711
- Locations
- 🇦🇺
Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
🇨🇦Health Sciences North, Sudbury, Ontario, Canada
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
- Conditions
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2020-06-11
- Target Recruit Count
- 79
- Registration Number
- NCT03926780
- Locations
- 🇪🇬
Andalusia Hospitals, Alexandria, Egypt
RIvoraxaban in Mitral Stenosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2021-08-19
- Target Recruit Count
- 40
- Registration Number
- NCT03926156
- Locations
- 🇮🇷
Rajaie Cardiovascular Medical and Research Center, Tehran, Iran, Islamic Republic of
Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Wuhan Asia Heart Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT03885180
- Locations
- 🇨🇳
Wuhan Asia Heart Hospital, Wuhan, Hubei, China
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Nicholas Carlson
- Target Recruit Count
- 718
- Registration Number
- NCT03862859
- Locations
- 🇩🇰
Department of Nephrology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
🇩🇰Aalborg University Hosptial, Aalborg, Denmark
🇩🇰Holbaek Hospital, Holbæk, Denmark
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45164
- Registration Number
- NCT03847181
- Locations
- 🇬🇧
Many facilities, Many Sites, United Kingdom
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 34
- Registration Number
- NCT03839355
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.